Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Pancreatic Cells Derived from Human Embryonic Stem Cells Cure Diabetes in Rodent Models

By BiotechDaily International staff writers
Posted on 12 Jul 2012
Commercially available human embryonic stem cells (hESCs) have been induced to differentiate into fully functional pancreatic beta cells that were capable of restoring insulin production and regularizing glucose metabolism in two different rodent diabetes models.

Investigators at the University of British Columbia (Vancouver, Canada) and their colleagues at the biotechnology firm BetaLogics (Raritan, NJ, USA) developed a protocol to differentiate commercially available human embryonic stem cells (hESCs) in vitro into a highly enriched PDX1+ pancreatic progenitor cell population. These cells progressed in vivo into mature pancreatic endocrine cells.

Immature pancreatic precursor cells were transplanted into immunodeficient mice with streptozotocin-induced diabetes. Glycemia was initially controlled with exogenous insulin; however, as insulin levels derived from the grafted stem cells increased over time, the mice were weaned from the insulin. Glucose metabolism was eventually regulated by meal and glucose challenges. Similar differentiation of pancreatic precursor cells was observed after transplant into immunodeficient rats.

Additional details published in the June 27, 2012, online edition of the journal Diabetes revealed that throughout the in vivo maturation period hESC-derived endocrine cells exhibited gene and protein expression profiles that were remarkably similar to that of cells in the developing human fetal pancreas.

"We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans," said senior author Dr. Timothy Kieffer, professor of cellular and physiological sciences at the University of British Columbia. "The studies were performed in diabetic mice that lacked a properly functioning immune system that would otherwise have rejected the cells. We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression."

Related Links:
University of British Columbia


Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.